Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
The most successful discontinuation outcomes occur when patients have already locked in behavioral changes: consistent meal timing, adequate protein intake, regular physical activity, and stress management
L.Frazer-MorrisC.ShillehA
Disproportionality analysis Disproportionality analysis represents a fundamental methodology in pharmacovigilance and drug safety surveillance, designed to identify potential safety signals through the detection of statistical imbalances in adverse drug reaction (ADR) reporting patterns
The rising prevalence of IBD worldwide and the ageing of the IBD population will likely increase the number of patients with metabolic comorbidities who may potentially benefit from a combination treatment with GLP-1 RAs
You want to lose fat while retaining muscle
US$ 22.82
US$ 25.48
US$ 24.26
US$ 22.47
US$ 29.90
